Opinions over Targets for Blood Pressure Control after Mechanical Thrombectomy in Patients with Acute Ischemic Stroke: Baseline Survey for the ENCHANTED2/MT Trial in China

Abstract

<b><i>Introduction:</i></b> Although guidelines recommend a target blood pressure 185–180/105–110 mm Hg after mechanical thrombectomy for acute ischemic stroke, there is limited randomized evidence to support this level. We surveyed candidate institutions about the approach to blood pressure management in this patient group in preparation for inviting them to participate in the Enhanced Blood Pressure Control after Endovascular Thrombectomy for the Acute Ischemic Stroke Trial (ENCHANTED2/MT). <b><i>Methods:</i></b> Physicians from a professional network of institutions that met mechanical thrombectomy qualification requirements were invited to participate in an online questionnaire covering basic clinical information as well as questions on blood pressure management. <b><i>Results:</i></b> We invited 88 sites to participate with 44 (50%) ultimately joining the trial, and a total of 88 physicians finished the survey. The median number of annual mechanical thrombectomy cases performed per site was 89 (IQR: 65–150). Only 38 (43%) institutions strictly adhere to guidelines when managing the blood pressure of mechanical thrombectomy patients. The most popular blood pressure target for reperfusion patients was 140–160 mm Hg (<i>n</i> = 47, 53%) and &lt;120 mm Hg (<i>n</i> = 28, 32%). Fewer hospital stroke beds (40 [21–57] vs. 60 [39–110], <i>p</i> = 0.01) and lower proportion of elevated blood pressure after mechanical thrombectomy (25% [10–50%] vs. 50% [20–70%], <i>p</i> = 0.02) were related to a more aggressive blood pressure target (&lt;120 mm Hg). Urapidil (<i>n</i> = 82, 93%) and calcium channel blockers (<i>n</i> = 87, 99%) were the most widely used antihypertensive drugs, respectively. <b><i>Conclusion:</i></b> According to the survey, unstandardized blood pressure management protocols are performed in mechanical thrombectomy patients at institutions across China, which is different from prior survey from another country. More high-quality studies are needed to guide clinical practice.